Fatigue Syndrome, Chronic
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune exhaustion in ME/CFS and long COVID.
Metabolomic and immune alterations in long COVID patients with chronic fatigue syndrome.
Myalgic encephalomyelitis: International Consensus Criteria.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q1 2027.
Clinical MilestonesViewHide
- 2026-06-22Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of CancerResults expected Q1 2027
- 2026-06-22ClinicalImproving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of CancerResults expected Q1 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes7
- Fatigue Syndrome, Chronic4
- COVID-192
- Fibromyalgia1
- International Classification of Diseases1
- Major Depressive Disorder1
- SARS-CoV-21
- Selenium1
Leading journals5
- Frontiers in immunology1
- JCI insight1
- Journal of internal medicine1
- Redox biology1
- Scientific reports1
Leading researchers8
- Marshall-Gradisnik S2
- Algon AAA1
- Almulla AF1
- Asaad S1
- Bateman L1
- Baumgarten-Austrheim B1
- Bell DS1
- Broderick G1
Affiliations (unnormalised)6
- Center of Excellence in Immunology and Immune-Mediated Diseases1
- Chulalongkorn University1
- Department of Laboratory Medicine1
- Institute for Biomedicine and Glycomics1
- Institute for Experimental Endocrinology1
- Key Laboratory of Psychosomatic Medicine1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Chronic fatigue syndrome is a syndrome marked by persistent or recurrent fatigue lasting at least 6 months, along with diffuse musculoskeletal pain, sleep disturbance, and subjective cognitive impairment. The symptoms are not explained by ongoing exertion, are not relieved by rest, and lead to a substantial reduction in occupational, educational, social, or personal functioning. The literature also notes considerable overlap with fibromyalgia.
The grounding does not identify a specific cause or aetiologic agent. The review abstract states that the label has persisted in part because of a lack of knowledge of the aetiological agents and disease process. Virology is among the literature aspects covered, but no specific infectious cause is supported here.
The MeSH definition notes minor alterations in immune, neuroendocrine, and autonomic function may be associated with the syndrome. The review abstract describes more recent research and clinical experience as pointing to widespread inflammation and multisystemic neuropathology. Cytokines are among the co-studied proteins, consistent with an immunologic component.
The supplied grounding does not support specific risk factors. It does indicate overlap with fibromyalgia, but that is not presented as a risk factor. No demographic, environmental, or infectious risk factors are established in the provided material.
The supplied grounding does not provide treatment guidance or a standard-of-care description. It includes immunology and virology as literature aspects, but no therapeutic modality or drug class is supported. Therefore this field is not supported by the grounding.
AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.